Happiness Biotech Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People’s Republic of China and internationally. More Details
Undervalued with excellent balance sheet.
Share Price & News
How has Happiness Biotech Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2UO1 is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 2UO1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
7 Day Return
DE Personal Products
1 Year Return
DE Personal Products
Return vs Industry: Insufficient data to determine how 2UO1 performed against the German Personal Products industry.
Return vs Market: Insufficient data to determine how 2UO1 performed against the German Market.
Long-Term Price Volatility Vs. Market
How volatile is Happiness Biotech Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Happiness Biotech Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2UO1 (€1.57) is trading below our estimate of fair value (€3.95)
Significantly Below Fair Value: 2UO1 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2UO1 is good value based on its PE Ratio (3.6x) compared to the XE Personal Products industry average (20.8x).
PE vs Market: 2UO1 is good value based on its PE Ratio (3.6x) compared to the German market (23.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2UO1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2UO1 is good value based on its PB Ratio (0.6x) compared to the XE Personal Products industry average (2.4x).
How is Happiness Biotech Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Happiness Biotech Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Happiness Biotech Group is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Happiness Biotech Group competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Household industry.
How has Happiness Biotech Group performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 2UO1 has high quality earnings.
Growing Profit Margin: 2UO1's current net profit margins (19.5%) are lower than last year (29.3%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2UO1's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: 2UO1's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2UO1 had negative earnings growth (-32.2%) over the past year, making it difficult to compare to the Personal Products industry average (16.3%).
Return on Equity
High ROE: 2UO1's Return on Equity (15.9%) is considered low.
How is Happiness Biotech Group's financial position?
Financial Position Analysis
Short Term Liabilities: 2UO1's short term assets ($70.0M) exceed its short term liabilities ($5.5M).
Long Term Liabilities: 2UO1 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 2UO1's debt to equity ratio (2.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 2UO1's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 2UO1's debt is well covered by operating cash flow (530.3%).
Interest Coverage: 2UO1's interest payments on its debt are well covered by EBIT (665x coverage).
What is Happiness Biotech Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2UO1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2UO1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2UO1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2UO1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2UO1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Xuezhu Wang (36 yo)
Mr. Xuezhu Wang has been Chief Executive Officer of Happiness Biotech Group Limited since August 28, 2018 and Executive Director since February 09, 2018. He has been the Chief Executive Officer of Fujian H...
CEO Compensation Analysis
Compensation vs Market: Xuezhu's total compensation ($USD25.59K) is below average for companies of similar size in the German market ($USD471.21K).
Compensation vs Earnings: Xuezhu's compensation has been consistent with company performance over the past year.
|CEO & Director||2.25yrs||US$25.59k||46.51% |
|Independent Director||1.08yrs||no data||no data|
|Independent Director||1.08yrs||no data||1.33% |
|Independent Director||1.08yrs||no data||no data|
|Director||no data||no data||no data|
Experienced Board: 2UO1's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.
Happiness Biotech Group Limited's company bio, employee growth, exchange listings and data sources
- Name: Happiness Biotech Group Limited
- Ticker: 2UO1
- Exchange: DB
- Founded: 2004
- Industry: Personal Products
- Sector: Household
- Market Cap: US$49.987m
- Listing Market Cap: US$41.984m
- Shares outstanding: 25.90m
- Website: https://www.happ.org.cn
Number of Employees
- Happiness Biotech Group Limited
- No. 11, Dongjiao East Road
- Fujian Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HAPP||NasdaqCM (Nasdaq Capital Market)||Yes||Ordinary Shares||US||USD||Oct 2019|
|2UO1||BST (Boerse-Stuttgart)||Yes||Ordinary Shares||DE||EUR||Oct 2019|
|2UO1||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Oct 2019|
Happiness Biotech Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People’s Republic of China and internationally. The compa...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/26 18:35|
|End of Day Share Price||2020/11/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.